Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663.

View in: PubMed

subject areas

Adult
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Cisplatin
Disease Progression
Disease-Free Survival
Drug Administration Schedule
Female
Humans
Infusions, Intravenous
Middle Aged
Paclitaxel
Topotecan
Uterine Cervical Neoplasms

authors with profiles

William Thomas Creasman